The emergence of TAVR has provided an alternative to surgery for many eligible high-risk patients suffering from aortic valve disease. With advancements in device development and novel technologies, the transcatheter approach to aortic valve replacement is poised to grow. The goal of these programs is to provide the audience with a foundation for the current role of TAVR in the treatment of patients with aortic stenosis in order to improve the knowledge and competence of attendees, thereby improving patient care and outcomes. The faculty will explore the criteria used in the treatment decision of TAVR versus surgical valve replacement is made, and clinical trial data will be analyzed and discussed to determine the potential expansion of TAVR as the standard of care for low- and intermediate-risk patients. Based on current evidence, the program will also address how TAVR outcomes can be improved and how TAVR centers can prepare for the potential expansion of TAVR into broader patient indications.